Frequency and impact of bleeding in elective coronary stent clinical trials-Utility of three commonly used definitions

Catheterization and Cardiovascular Interventions

Volumn 80, Issue 2, 2012, Pages

  Fleming, Lisa M ^a   Novack, Victor ^b   Novack, Lena ^b   Cohen, Sidney A ^c,e   Negoita, Manuela ^d   Cutlip, Donald E ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^c Department of Medical Affairs and Health Ecomomics Worldwide   (United States)

^d MEDTRONIC INC   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

bleeding; stent

Indexed keywords

PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; CARDIOVASCULAR MORTALITY; CORONARY STENT; CRITERION VARIABLE; DATA ANALYSIS; DEVICE SAFETY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; ELECTIVE SURGERY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; POPULATION RESEARCH; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CLINICAL TRIALS AS TOPIC; DRUG-ELUTING STENTS; ENDPOINT DETERMINATION; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; TERMINOLOGY AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864284414     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.23332     Document Type: Article

References (35)

1. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92: 930-935. (Pubitemid 37214804)
2. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853-863. (Pubitemid 37430344)
3. Sobieraj-Teague M, Gallus AS, Eikelboom JW,. The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality. Curr Opin Cardiol 2008; 23: 327-334. (Pubitemid 351787097)
4. Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, et al. Acute catheterization and urgent intervention triage strategy (ACUITY) trial: Study design and rationale. Am Heart J 2004; 148: 764-775.
5. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-2216. (Pubitemid 44791162)
6. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: An analysis from the ACUITY trial. J Am Coll Cardiol 2007; 49: 1362-1368. (Pubitemid 46476844)
7. Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, Topol EJ, Manoukian SV,. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol 2007; 100: 1364-1369. (Pubitemid 47576015)
8. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S,. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782. (Pubitemid 44268228)
9. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, Mahaffey KW, Califf RM, Harrington RA,. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96: 1200-1206. (Pubitemid 41505393)
10. Segev A, Strauss BH, Tan M, Constance C, Langer A, Goodman SG,. Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: Insights from the Canadian Acute Coronary Syndrome Registries. Am Heart J 2005; 150: 690-694. (Pubitemid 41396500)
11. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schomig A, Kastrati A,. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: Appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008; 51: 690-697. (Pubitemid 351221218)
12. Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: Assessment from the acute catheterization and urgent intervention triage strategy trial. Circulation 2010; 121: 43-51.
13. Lindsey JB, Marso SP, Pencina M, Stolker JM, Kennedy KF, et al. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: Results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. JACC Cardiovasc Interv 2009; 2: 1074-1082.
14. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323. (Pubitemid 37186209)
15. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231. (Pubitemid 38067635)
16. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two-year clinical follow-up from the clinical evaluation of the Xience V Everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation 2009; 119: 680-686.
17. Leon MB, Mauri L, Popma JJ, Cutlip DE, Nikolsky E, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 2010; 55: 543-554.
18. Steinhubl SR, Kastrati A, Berger PB,. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. Am Heart J 2007; 154: 3-11. (Pubitemid 46924806)
19. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006; 47: 809-816. (Pubitemid 43243106)
20. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G,. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomized controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-1099. (Pubitemid 37222332)
21. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ,. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43: 1110-1115. (Pubitemid 38352997)
22. Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine- encapsulated stent system in de novo native coronary artery lesions: Endeavor I trial. Eurointervention 2005; 1: 157-164.
23. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE,. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the Endeavor II trial. Minerva Cardioangiol 2007; 55: 1-18. (Pubitemid 46480820)
24. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: A randomized controlled trial. J Am Coll Cardiol 2006; 48: 2440-2447. (Pubitemid 44881222)
25. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, et al. Thrombolysis in myocardial infarction (TIMI) trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76: 142-154. (Pubitemid 17093202)
26. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
27. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351. (Pubitemid 46685903)
28. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, et al. Universal definition of myocardial infarction. Circulation 2007; 116: 2634-2653. (Pubitemid 350182388)
29. Doyle BJ, Ting HH, Bell MR, Lennon RJ, Mathew V, Singh M, Holmes DR, Rihal CS,. Major femoral bleeding complications after percutaneous coronary intervention: Incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. JACC Cardiovasc Interv 2008; 1: 202-209. (Pubitemid 351506552)
30. Kim P, Dixon S, Eisenbrey AB, O'Malley B, Boura J, O'Neill W,. Impact of acute blood loss anemia and red blood cell transfusion on mortality after percutaneous coronary intervention. Clin Cardiol 2007; 30: II35-II43. (Pubitemid 47587497)
31. Yatskar L, Selzer F, Feit F, Cohen HA, Jacobs AK, Williams DO, Slater J,. Access site hematoma requiring blood transfusion predicts mortality in patients undergoing percutaneous coronary intervention: Data from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheter Cardiovasc Interv 2007; 69: 961-966. (Pubitemid 46897929)
32. Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, White K, Goldberg RJ,. Predictors of major bleeding in acute coronary syndromes: The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815-1823. (Pubitemid 37280247)
33. Mehta SK, Frutkin AD, Lindsey JB, House JA, Spertus JA, Rao SV, Ou FS, Roe MT, Peterson ED, Marso SP,. Bleeding in patients undergoing percutaneous coronary intervention: The development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv 2009; 2: 222-229.
34. Montalescot G, Gallo R, White HD, Cohen M, Steg PG, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. JACC Cardiovasc Interv 2009; 2: 1083-1091.
35. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H,. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the bleeding academic research consortium. Circulation 2011; 123: 2736-2747.